The MaxDiscovery™ Luciferase ELISA Kit is an enzyme immunoassay that analyzes the quantity of Luciferase in cells, serum and tissues. Luciferase is a generic name for enzymes, commonly found in nature, that produce light. The most commonly used Luciferase is produced by, Photinus pyralis, the American firefly, which can catalyze a chemiluminescent oxidation–reduction reaction. Although many kits are available to detect the enzymatic activity of this protein using light emission, these methods have several drawbacks. For example, these assays have rapid decay kinetics and require the enzymatic activity of the Luciferase to be retained. Since enzyme activity can be influenced by many factors including handling, storage and buffer conditions, these assays are more variable and more difficult to reproduce than ELISA based assays. In addition, enzyme based activity assays do not easily enable absolute quantification as enzyme activity is relative to a standard that does not contain equal representative activity with respect to the quantity of luciferase. In response to these issues, Bioo Scientific has developed a highly sensitive ELISA assay which allows the researcher to completely measure the amount of firefly Luciferase protein from a number of sources. Like most ELISA assays, the MaxDiscovery™ Luciferase ELISA kit relies on a Horseradish Peroxidase (HRP) conjugated Luciferase antibody and the TMB (3,3´,5,5´-tetramethylbenzidine) substrate. TMB is a chromogen that yields a blue color when oxidized with hydrogen peroxide (catalyzed by HRP) and has major absorbances at 370 nm and 652 nm. The color then changes to yellow with the addition of acid with maximum absorbance at 450 nm. The relative amount of Luciferase protein in the cells will be directly proportional to the amount of signal that is obtained at 450 nm.
Charting Kidney Cancer Metabolism Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.Insights into the Function of the Main Class of Drug Targets About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.Visualizing a Cancer Drug Target at Atomic Resolution Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.Honey’s Potential to Save Lives The healing powers of honey have been known for thousands of years. 3-D Printed Lifelike Liver Tissue for Drug Screening A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling. Cytoskeleton Crew Findings confirm sugar's role in helping cancers survive by changing cellular architecture.Biomarker for Recurring HPV-Linked Oropharyngeal Cancers A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University. Valvena, GSK Sign New R&D Collaboration Valneva to supply process development services for EB66® -based Influenza vaccines. Light Signals from Living Cells Fluorescent protein markers delivered under high pressure.Cellular 'Relief Valve' A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.